Last updated on December 2014

EINSTEIN CHOICE


Brief description of study

EINSTEIN CHOICE

Detailed Study Description

EINSTEIN CHOICE is a phase II study designed to evaluate whether once-daily rivaroxaban in doses of 10mg or 20mg is superior to aspirin for the prevention of symptomatic recurrent DVT and/or PE in patients who have completed between six and 12 months of anticoagulant therapy. The study will include approximately 2,850 patients in 31 countries and currently is enrolling participants.

Clinical Study Identifier: TX139798

Find a site near you

Start Over

UNC Rex Healthcare

4420 Lake Boone Trail Raleigh, NC USA
  Connect »